Novo to acquire Catalent



Novo Nordisk A/S has announced plans to increase capacity for the supply of its medicines for diabetes and obesity in a staged transaction under which a subsidiary of its controlling shareholder, Novo Holdings A/S, will take over Catalent Inc, one the world’s largest contract manufacturing organisations (CMO). Announced on 5 February, the deal is expected to complete towards the end of 2024.